Learning to Live in a World Without a Loved One
How can we cope with loss and navigate the grieving process? By Lucy Hone | June 2, 2021
Coping with the loss of a loved one is hard at the best of times. At the worst of times, as COVID-19 continues to ravage the planet, it can be even harder to bear. Not only has the virus caused the unexpected, sudden deaths of so many, but the circumstances accompanying those deaths and the limitations the pandemic placed on mourners have made the grieving process that much harder to navigate.
In my capacity as co-director of the New Zealand Institute of Wellbeing & Resilience, I’ve been working with companies around the world to support the resilience of their teams throughout the pandemic. The multitude of grief stories has been harrowing. Only this week I spoke to a client whose work colleague had lost four members of his family to the virus. I’ve also spent time supporting a family whose husband/father was dying in
New inhibitors may offer novel approach to treating deadly tuberculosis
Zhong-Yin Zhang, head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology, developed highly potent and selective compounds for use in the treatment of tuberculosis. (Image provided)
WEST LAFAYETTE, Ind. – Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.
Purdue University innovators developed a stabilized form of human calcitonin, which is a peptide drug already used for people with osteoporosis. Researchers at Purdue created a prodrug form of the peptide hormone to increase its effectiveness as an osteoporosis treatment.